A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor
Phase: PHASE4
Conditions: Labor; Forced or Induced, Affecting Fetus or Newborn, Pregnancy
Sponsor: Milton S. Hershey Medical Center

Page 1 of 21 (V.04/20/2016)
HRP-592 - Protocol for Human Subject 
Research with Use of Test Article(s)
Protocol Title:
 A comparison of oral misoprostol versus vaginal misoprostol for cervical ripening and induction of labor
Principal Investigator:
Name: Jaimey Pauli, MD
Department: Maternal & Fetal Medicine
Telephone: 717-531-8142 (Extension #5)
E-mail Address: jpauli@pennstatehealth.psu.edu 
Co-Principal Investigator:
Name: Courtney Birchall, MD
Department: Obstetrics and Gynecology
Telephone: 717-531-3503
E-mail Address: cbirchall@pennstatehealth.psu.edu
Version Date:  2/1/2021
Clinicaltrials.gov Registration #:  NCT02777190
Important Instructions for Using This Protocol Template:
1.
Add this completed protocol template to your study in CATS IRB (http://irb.psu.edu) on the “Basic Information” 
page, item 7. 
2.
This template is provided to help investigators prepare a protocol that includes the necessary information needed 
by the IRB to determine whether a study meets all applicable criteria for approval. 
3.
Type your protocol responses below the gray instructional boxes of guidance language.  If the section or item is 
not applicable, indicate not applicable.
4.
For research being conducted at Penn State Hershey or by Penn State Hershey researchers only, delete the 
instructional boxes from the final version of the protocol prior to upload to CATS IRB (http://irb.psu.edu).  For all 
other research, do not delete the instructional boxes from the final version of the protocol.
5.
When making revisions to this protocol as requested by the IRB, please follow the instructions outlined in the Study 
Submission Guide available in the Help Center in CATS IRB (http://irb.psu.edu) for using track changes. 
If you need help…
University Park and other campuses:
Office for Research Protections Human Research Protection Program
The 330 Building, Suite 205
University Park, PA 16802-7014
Phone: 814-865-1775
Fax: 814-863-8699
Email: irb-orp@psu.edu
College of Medicine and Hershey Medical Center:
Human Subjects Protection Office
90 Hope Drive, Mail Code A115, P.O. Box 855
Hershey, PA 17033
(Physical Office Location: Academic Support Building Room 1140)
Phone: 717-531-5687
Fax number: 717-531-3937
Email: irb-hspo@psu.edu
STUDY00005107
Approval: 9/15/2021

Page 2 of 21 (V.04/20/2016)
Table of Contents
1.0
Objectives
2.0
Background
3.0
Inclusion and Exclusion Criteria
4.0
Recruitment Methods
5.0
Consent Process and Documentation
6.0
HIPAA Research Authorization and/or Waiver or Alteration of Authorization
7.0
Study Design and Procedures
8.0
Subject Numbers and Statistical Plan
9.0
Confidentiality, Privacy and Data Management
10.0
Data and Safety Monitoring Plan
11.0
Risks
12.0
Potential Benefits to Subjects and Others
13.0
Sharing Results with Subjects
14.0
Subject Stipend (Compensation) and/or Travel Reimbursements
15.0
Economic Burden to Subjects
16.0
Resources Available
17.0
Other Approvals
18.0
Multi-Site Research
19.0
Adverse Event Reporting
20.0
Study Monitoring, Auditing and Inspecting
21.0
Future Undetermined Research: Data and Specimen Banking
22.0
References
STUDY00005107
Approval: 9/15/2021

Page 3 of 21 (V.04/20/2016)
1.0
Objectives
1.1
Study Objectives
To study if misoprostol administered orally is at least as effective as misoprostol administered vaginally 
for cervical ripening and the induction of labor. The main purpose is to show that oral misoprostol 
administration is non-inferior to vaginal misoprostol administration with respect to the time interval 
from misoprostol administration to onset of active phase of labor. 
1.2
Primary Study Endpoints
The primary endpoint will be the time interval from administration of misoprostol to active phase of 
labor (greater than or equal to 6 cm dilation).
1.3
Secondary Study Endpoints
1.
Time interval from administration of misoprostol to initiation of oxytocin for continued 
augmentation of labor
2.
Time interval from administration of misoprostol to vaginal delivery
3.
Cesarean section rate
4.
Rate of vaginal delivery within 24 hours
5.
Rate of abandoning misoprostol for cervical ripening and switching to mechanical dilation for 
cervical ripening (ie, Foley balloon)
6.
Rate of development of preeclampsia requiring magnesium sulfate administration
7.
Rate of tachysystole
8.
Rate of tachysystole causing non-reassuring fetal heart tones
9.
Rate of need for tocolysis
10. Rate of chorioamnionitis
11. Rate of meconium stained fluid
12. Neonatal morbidity (composite outcome)
a.
Apgar of less than 7 at 5 minutes
b.
Fetal arterial umbilical cord gas with pH of less than 7 or base deficit great than 12
c.
NICU admission within 4 hours of delivery
13. Maternal side effects
a.
Rate of anti-emetic use
b.
Rate of diarrhea
14. Treatment emergent serious adverse events
a.
Uterine rupture
b.
Cesarean hysterectomy
c.
Maternal death during her hospitalization
d.
Neonatal death (0-28 days of life) related to the study drug
15. Adverse events
a.
Postpartum hemorrhage requiring blood transfusion
b.
Maternal surgical ICU admission
c.
Neonatal NICU admission during mother’s hospital admission
2.0
Background
2.1
Scientific Background and Gaps
There has always been a push to shorten the time interval a patient is on Labor and Delivery due to the 
added cost and resources that a patient needs in this setting. Methods used to shorten the time interval 
on Labor and Delivery need to remain safe, effective, and avoid raising the rate of cesarean delivery. 
One of the main reasons patients are on the Labor and Delivery unit for extended periods of time is for 
cervical ripening and induction of labor. Many methods have been studied to shorten the time of latent 
phase of labor which is normally the longest portion of the induction of labor. A standard method of 
STUDY00005107
Approval: 9/15/2021

Page 4 of 21 (V.04/20/2016)
cervical ripening and induction of labor is to use misoprostol administered vaginally every 4 hours. 
Misoprostol was originally approved by the FDA for reducing the risk of NSAID induced gastric ulcers. It 
does have a black box warning against its use in pregnancy, but then in 2002 had a new label stating its 
use during pregnancy for cervical ripening and induction of labor. [1] The American Congress of 
Obstetricians and Gynecologists (ACOG) have also supported the use of misoprostol that it is a safe and 
effective form of cervical ripening and induction of labor. [2] Misoprostol administered vaginally can 
have its downfalls due to requiring increased demands on the licensed provider (physician or midwife) 
to be present to administer the drug, increased amount of vaginal exams that may lead to increased rate 
of ascending infection, and inconsistency of dosing due to proper placement and use of lubricant, water, 
or no lubricant upon placement. [3] Since misoprostol administered orally has been proven safe, it may 
be an effective route of cervical ripening and induction of labor that requires fewer demands on the 
licensed provider and greater satisfaction for the patient when compared to misoprostol administered 
vaginally. 
2.2
Previous Data
The Cochrane review of “Oral misoprostol for induction of labour” stated that misoprostol administered 
orally was more effective than placebo, as effective as vaginal misoprostol, and fewer cesarean sections 
than vaginal dinoprostone or oxytocin. [3] The article stated that more randomized trials are needed, 
but their optimal dosage of oral misoprostol is 20 to 25 mcg administered in solution every 2 hours. The 
WHO in 2013 also recommended misoprostol be administered 25 mcg orally every 2 hours for induction 
of labor. [4] There are multiple studies that look at the oral misoprostol administered as 50 mcg every 4 
hours and oral misoprostol as a titration given every 1 hour, but no studies have been reported yet on 
the oral misoprostol administration of 25 mcg every 2 hours. There is also a pharmacokinetics study of 
misoprostol with oral versus vaginal administration that showed plasma levels of misoprostol fall sharply 
after 2 hours when administered orally while the peak plasma levels are sustained for up to 4 hours 
when administered vaginally. [5] Using the pharmacokinetics data, the oral misoprostol treatment arm 
will be dosed more frequently than the vaginal misoprostol treatment arm to maintain plasma levels of 
misoprostol throughout the study period. 
2.3
Study Rationale
To show that misoprostol administered orally is at least as effective as misoprostol administered 
vaginally for cervical ripening and induction of labor, since it is not commonly used at Hershey Medical 
Center, it can be utilized to lessen the burden on licensed practitioners, decrease infection rate from less 
vaginal exams, increase patient satisfaction due to less vaginal exams, and test the dosing the oral 
misoprostol that the Cochrane review and WHO suggest. 
3.0
Inclusion and Exclusion Criteria
3.1
Inclusion Criteria
1.
Pregnant Female Patients greater than or equal to 18 years of age
2.
Induction of labor for a single live intrauterine pregnancy 
a.
For medical indications for induction of labor, must be greater than or equal to 37 weeks 
gestational age and meet one of the following criteria for the induction of labor (taken from 
ACOG Practice Bulletin Number 107) [2]
i.
Abruptio placentae
ii.
Chorioamnionitis
iii.
Gestational hypertension
iv.
Late term (41 weeks) or postterm (42 weeks) pregnancy
v.
Maternal medical conditions (eg, diabetes mellitus, renal disease, chronic pulmonary 
disease, chronic hypertension, antiphospholipid syndrome)
vi.
Fetal compromise (eg, isoimmunization, oligohydramnios)
STUDY00005107
Approval: 9/15/2021

Page 5 of 21 (V.04/20/2016)
b.
For elective inductions of labor that do not meet the above medical indications, must be greater 
than or equal to 39 weeks gestational age and meet one of the following criteria. 
i.
Ultrasound measurement at less than 20 weeks of gestation supporting gestational age 
of 39 weeks or greater
ii.
Fetal heart tones documented as present for 30 weeks by Doppler ultrasonography
iii.
36 weeks since positive serum or urine human chorionic gonadotropin pregnancy test 
result
iv.
Documented fetal lung maturity
3.
Cephalic presentation
4.
20 minute reassuring fetal heart rate (reactive nonstress test (NST)) 
5.
Bishop score based on sterile vaginal exam of less than or equal to 6, for which the cervical dilation is 
less than or equal to 2 cm.
6.
Equal to 3 or less uterine contractions over 10 minutes
3.2
Exclusion Criteria
1.
Previous uterine scar from either prior cesarean section or major uterine surgery
2.
Contraindication to vaginal delivery
3.
Patients with preeclampsia
4.
Premature rupture of membranes
5.
Suspected intrauterine fetal growth restriction
6.
Fetal anomalies
7.
Grand multiparity – greater than or equal to 5 live births or stillbirths (greater than or equal to 20 weeks 
of gestation) 
8.
Contraindication to misoprostol (history of allergy to prostaglandins, glaucoma)
3.3
Early Withdrawal of Subjects
3.3.1
Criteria for removal from study
Individual subjects who desire to be withdrawn from the study or who withdraw their consent 
to be in the study at any time will be removed from the study and continue their care in a 
routine fashion.  If the patient experiences an unexpected allergic reaction to the study drug 
(evidenced by hives, rash, swelling, or difficulty breathing), the patient will be immediately 
withdrawn from study participation and will no longer receive the study drug.  If the patient 
experiences a serious adverse event (uterine rupture) while taking study drug, she will be 
removed from the study and no longer receive study drug.  Any serious adverse event that 
occurs after delivery (maternal death during hospitalization, neonatal death during 
hospitalization, cesarean hysterectomy) does not warrant removal from study since study drug 
would already be terminated.      
3.3.2
Follow-up for withdrawn subjects
Withdrawn subject’s data can still be obtained from the subject’s chart and incorporated into 
the data analysis. Subjects who have withdrawn from the study will still have their routine 
follow-up with their physician.
4.0
Recruitment Methods
4.1
Identification of subjects
When scheduling any term induction of labor in the office, patients can be approached as potential 
subjects for the study. Offices would include the Women’s Health Division at Hope Drive, Camp Hill, 
Nyes Road, and Mt. Joy along with Maternal Fetal Medicine Department. Also, when on Labor and 
Delivery term patients coming in for induction of labor can be approached as potential subjects.  
Patients will be identified by the physicians. 
STUDY00005107
Approval: 9/15/2021

Page 6 of 21 (V.04/20/2016)
4.2
Recruitment process
Patients will be recruited by physicians that are involved in this study. They will be notified of the study 
in the office when their induction of labor is scheduled or on Labor and Delivery when they arrive for 
their induction of labor. While on Labor and Delivery potential subjects must have a Bishop score of less 
than or equal to 6 and adequate fetal heart rate testing.  They will be counseled by the physician about 
methods of cervical ripening and induction of labor.  After potential subjects meet all inclusion/exclusion 
criteria, they can then be offered to be in this research study. 
4.3
Recruitment materials
If subjects meet the inclusion/exclusion criteria they will be offered to be in this research study and will 
receive a copy of the consent form to review. A flyer and/or PowerPoint slide will be posted in the 
offices and Labor and Delivery to notify physicians and advance practitioners of potential subjects for 
the study. The flyer and PowerPoint slide are for faculty and staff only and not patient handouts.
4.4
Eligibility/screening of subjects
If a woman is interested in participating in the study, all procedures will be explained to her before she 
signs consent.  Interested women will be screened for eligibility based on the inclusion/exclusion criteria  
and will be given the opportunity to ask any questions about the study. 
5.0
Consent Process and Documentation
5.1
Consent Process 
 
5.1.1
Obtaining Informed Consent
5.1.1.1 Timing and Location of Consent
Informed consent will be obtained on the Labor and Delivery Unit at the time prior to 
the subject’s induction of labor. 
5.1.1.2 Coercion or Undue Influence during Consent
All methods of cervical ripening and induction of labor must be explained to the patient 
prior to signing the consent form. Vaginal misoprostol has been shown to have less use 
of epidural analgesia, more vaginal deliveries in 24 hours, and higher rate of uterine 
tachysystole as compared to dinoprostone gel or oxytocin. [6] Mechanical ripening with 
Foley catheter showed no difference when compared to dinoprostone gel. [2] The use of 
vaginal misoprostol has been associated with higher rates of uterine tachysystole and a 
Foley catheter has been associated with the lowest rate of uterine tachysystole. [7] Oral 
misoprostol has been shown to have the lowest rate of cesarean section. [3, 7, 8] Along 
with that oral misoprostol has been shown to have added safety benefits in a reduction 
in Apgar score of less than 7 at five minutes and reduced uterine tachysytole when 
compared with vaginal misoprostol. [6] 
Additionally, patients will be informed verbally and in writing that participation in the 
study is voluntary and they may withdraw from the study at any time.  Whether or not 
patients agree to participate in this study, it will not affect their labor and delivery 
options available to them.
5.1.2
Waiver or alteration of the informed consent requirement
 Waiver of informed consent requested for screening/recruitment purposes only.
STUDY00005107
Approval: 9/15/2021

Page 7 of 21 (V.04/20/2016)
5.2
Consent Documentation
5.2.1
Written Documentation of Consent
Written consent will be obtained prior to subject’s enrollment. The physician will review the consent 
form with the subject and ensure that the subject thoroughly understands the study and allows 
adequate time for the patient to review the consent.  The patient and physician will sign and date the 
consent form on Labor and Delivery at Hershey Medical Center prior to their induction of labor. The 
patient will then receive a signed and dated copy of the consent and then the consent form will be 
stored in a doubly locked Maternal Fetal Medicine office to prevent unauthorized access to patient 
information. 
5.2.2
Waiver of Documentation of Consent (Implied consent, Verbal consent, etc.)
N/A
5.3
Consent – Other Considerations 
5.3.1
Non-English Speaking Subjects
The inclusion of non-English speaking participants is not planned.  
5.3.2
Cognitively Impaired Adults
5.3.2.1 Capability of Providing Consent
Patient’s already sign consent for medical treatment and possible cesarean section, which 
is standard upon admission into the Labor and Delivery Unit.  If these patients are able to 
sign and understand the consent upon admission to Labor and Delivery, then they have 
adequate decision making ability to be included in this study. 
5.3.2.2 Adults Unable To Consent
If subjects are unable to perform informed consent they will not be included in the study, 
including those than cannot read or write. 
5.3.2.3 Assent of Adults Unable to Consent
Assent will not be required in this study. Only subjects who are able to consent will be 
included. 
5.3.3
Subjects who are not yet adults (infants, children, teenagers) 
5.3.3.1 Parental Permission
N/A
5.3.3.2 Assent of subjects who are not yet adults
N/A
6.0
HIPAA Research Authorization and/or Waiver or Alteration of Authorization
6.1
Authorization and/or Waiver or Alteration of Authorization for the Uses and Disclosures of PHI
Check all that apply:
 
Not applicable, no identifiable protected health information (PHI) is accessed, used or 
disclosed in this study. [Mark all parts of sections 6.2 and 6.3 as not applicable]
Authorization will be obtained and documented as part of the consent process. [If this is the 
only box checked, mark sections 6.2 and 6.3 as not applicable]
STUDY00005107
Approval: 9/15/2021

Page 8 of 21 (V.04/20/2016)
Partial waiver is requested for recruitment purposes only (Check this box if patients’ medical 
records will be accessed to determine eligibility before consent/authorization has been 
obtained). [Complete all parts of sections 6.2 and 6.3]
Full waiver is requested for entire research study (e.g., medical record review studies). 
[Complete all parts of sections 6.2 and 6.3]
Alteration is requested to waive requirement for written documentation of authorization 
(verbal authorization will be obtained). [Complete all parts of sections 6.2 and 6.3]
6.2
Waiver or Alteration of Authorization for the Uses and Disclosures of PHI
6.2.1
Access, use or disclosure of PHI representing no more than a minimal risk to the privacy of the 
individual
6.2.1.1 Plan to protect PHI from improper use or disclosure
Information is included in the “Confidentiality, Privacy and Data Management” section 
of this protocol.
6.2.1.2 Plan to destroy identifiers or a justification for retaining identifiers 
Identifiers will include medical record number, patient name, and date of birth. Data will 
be stored in a secure web application as outlined below. Data will be de-identified with 
removal of PHI when abstracted and stored on a secure server for statistical analysis.
6.2.2
Explanation for why the research could not practicably be conducted without access to and 
use of PHI
Without PHI it would be impossible to identify patients who would be eligible for this 
study. 
6.2.3
Explanation for why the research could not practicably be conducted without the waiver or 
alteration of authorization
Without access to the subject’s medical record it would be impossible to perform collection of 
data for this prospective randomized study. 
6.3
Waiver or alteration of authorization statements of agreement
Protected health information obtained as part of this research will not be reused or disclosed to any 
other person or entity, except as required by law, for authorized oversight of the research study, or for 
other permitted uses and disclosures according to federal regulations. 
The research team will collect only information essential to the study and in accord with the ‘Minimum 
Necessary’ standard (information reasonably necessary to accomplish the objectives of the research) 
per federal regulations. 
Access to the information will be limited, to the greatest extent possible, within the research team. All 
disclosures or releases of identifiable information granted under this waiver will be accounted for and 
documented.
7.0
Study Design and Procedures
7.1
Study Design
Non-inferiority, prospective, open-label, randomized controlled trial.
STUDY00005107
Approval: 9/15/2021

Page 9 of 21 (V.04/20/2016)
Subjects included in the study will be randomized to receive misoprostol for cervical ripening and labor 
induction either orally or vaginally.
In the oral misoprostol group, subjects will receive misoprostol 25 mcg PO every 2 hours (range 2-3 hours). 
Misoprostol will be administered by the nurse with a sip of water. 
In the vaginal misoprostol group, subjects will receive misoprostol 25 mcg vaginally every 4 hours (range 4-5 
hours). The physician will place the misoprostol 25 mcg per vagina in the posterior fornix of the vagina with 
minimal sterile gel for lubricant, usually requiring less than ½ packet of sterile gel. 
For redosing for both groups, subject can receive repeat dosing if there are 3 or fewer contractions per 10 
minutes and a Category I fetal heart rate tracing. 
In the oral misoprostol group, redosing will be considered 2 hours (range 2-3 hours) after a dose of oral 
misoprostol was given. At the time of evaluation if there are 3 or fewer contractions per 10 minutes and a 
Category I fetal heart rate tracing, an oral misoprostol dose will be given. If at the time of evaluation there are 4 
or more contractions per 10 minute or a Category II fetal heart rate tracing, the provider will wait 2 hours (range 
2-3 hours) to reassess if redosing is appropriate. If there is a Category II fetal heart rate tracing and the provider 
is uncomfortable waiting to reassess, they may proceed with clinical management per the primary team and if 
deemed appropriate, reassess in two hours.   Then upon the reassessment it would be 4 hours since the last oral 
misoprostol dose and a vaginal exam may occur as part of the assessment for redosing. If at the reassessment 
for a second time in a row there is a Category II fetal heart rate tracing and misoprostol cannot be given, the 
protocol can be abandoned and the provider can proceed with induction of labor and/or delivery as they see fit 
based on their medical judgement. If reassessing for the second time in a row with failure to give a dose of oral 
misoprostol due to greater than or equal to 4 contractions in 10 minutes, provider may stop misoprostol 
protocol and transition to oxytocin and titrate up per protocol. Vaginal exams will be timed appropriately to be 
at every 4 hours (range 4-5 hours) when reassessing oral misoprostol dose. 
In the vaginal misoprostol group, redosing will be considered 4 hours (range 4-5 hours) after a dose of vaginal 
misoprostol was given. At the time of evaluation if there are 3 or fewer contractions per 10 minutes, a Category I 
fetal heart rate tracing, and a Bishop score of less than 8 or cervical exam less than 4 cm, a vaginal misoprostol 
dose will be given. At the time of evaluation if there are 4 or more contractions per 10 minutes or a Category II 
fetal heart rate tracing, redosing will be withheld and reassessed in 2 hours (range 2-3 hours). If there is a 
Category II fetal heart rate tracing and the provider is uncomfortable waiting to reassess, they may proceed with 
clinical management per the primary team and if deemed appropriate, reassess in two hours. Ifat time of 
reassessment misoprostol is again unable to be given due to a Category II fetal heart rate tracing, the protocol 
can be abandoned and the provider can proceed with induction of labor and/or delivery as they see fit based on 
their medical judgement. If market time of reassessment vaginal misoprostol is again unable to be given due to 
4 or more contractions per 10 minutes, then the provider may stop the misoprostol protocol and transition to 
oxytocin and titrate up per protocol. Vaginal exams will occur every 4 hours (range 4-5 hours) after a vaginal 
misoprostol dose was given. 
Redosing will be withheld if the Bishop score is greater than or equal to 8, cervical dilation is greater than or 
equal to 4 cm, active labor is established, if there is a fetal heart tracing that is Category III, or if the subject has 
spontaneous rupture of membranes. If any of these criteria are met, misoprostol protocol will be stopped and 
transitioned to oxytocin as appropriate and titrated up per protocol. If there is a Category III fetal heart tracing, 
the misoprostol protocol will be stopped, and the clinical management will proceed per the primary team.  
Subjects may only have a maximum of 6 doses of misoprostol vaginally for a total of 150 mcg and may only have 
a maximum of 12 doses of misoprostol orally for a total of 300 mcg. 
Active labor is when the cervix is 6 cm or greater in dilation with regular uterine contractions. 
STUDY00005107
Approval: 9/15/2021

Page 10 of 21 (V.04/20/2016)
Oxytocin should not be administered until 4 hours after the last dose of misoprostol if given vaginally or 2 hours 
after the last dose of misoprostol if given orally. Oxytocin transition and titration will follow the Penn State 
Hershey Medical Center oxytocin 30units/500mL lactated ringers solution LOW DOSE Regimen protocol which 
starts at 2 mUnit/min and titrates up by 2 mUnit/min every 30 minutes. 
If the patient has spontaneous rupture of membranes while undergoing misoprostol administration they should 
be transitioned to oxytocin and not receive another dose of misoprostol. The oxytocin will be titrated per 
protocol. Artificial rupture of membrane may be up to physician discretion after the initiation of oxytocin. 
Mechanical dilation, such as Foley catheter or Cook balloon, is not to be used during the induction of labor, 
unless the patient has reached 24 hours of cervical ripening with misoprostol and no more doses are available. 
7.2
Study Procedures
On Labor and Delivery will have continuous fetal heart rate and tocodynanameter monitoring. During 
misoprostol administration provider will perform sterile vaginal exams approximately every 4 hours (range 4-5 
hours). After misoprostol administration is completed, provider will perform sterile vaginal exams every 2 hours 
(range 1-3 hours). When the subject reaches active labor of greater than or equal to 6 cm dilated, they will be 
questioned if they had any diarrhea up to this point and it will be documented if an antiemetic was used. 
Subject’s vital signs will be taken every hour as routine protocol at Hershey Medical Center. It will be noted if 
there is meconium stained amniotic fluid. Umbilical cord gases will be obtained on every subject. 
7.2.1
EXAMPLE: Visit 1 or Day 1 or Pre-test, etc. (format accordingly)
In office when scheduling induction of labor may have sterile vaginal exam to see if patient meets 
inclusion criteria of Bishop score less than or equal to 6. 
7.2.2
EXAMPLE: Visit 2 or Day 2 or Post-test, etc. (format accordingly)
On Labor and Delivery will have continuous fetal heart rate and tocodynanameter monitoring. During 
misoprostol administration provider will perform sterile vaginal exams every 4 hours (range 4-5 hours). 
After misoprostol administration is completed, provider will perform sterile vaginal exams every 2 hours 
(range 1-3 hours). Nurse or provider will document every 2 hours if patient subjectively states they are 
nauseated or have had diarrhea. Nurse or provider will document the amount of times anti-emetics 
were administered. Subject’s vital signs will be taken every hour as routine protocol at Hershey Medical 
Center. It will be noted if there is meconium stained amniotic fluid. Umbilical cord gases will be obtained 
on every subject. 
7.3
Duration of Participation
The time it takes for the subject’s initiation of induction of labor to delivery of infant. 
7.4
Test Article(s) (Study Drug(s) and/or Study Device(s))
7.4.1
Description
Misoprostol is currently available in 100 mcg tablets. The 100 mcg tablet will be divided into 4 
equal pieces to become a 25 mcg tablet. The 25 mcg tablet will be used for the study. There is a 
small margin of error in creating an exactly 25 mcg tablet since there are no scores on the 100 
mcg tablet. When dividing the 100 mcg tablet into four pieces, if any of the ¼ tablets judged to 
appear uneven based on weight they will be discharged at time of preparation. To assist in this 
judgment, pharmacy will weigh 10 tablets of misoprostol to calculate what an average ¼ piece 
should weigh. If a ¼ tablet weighs 5% greater difference than what it’s estimated weight should 
be, it will be discarded. If all 4 pieces appear appropriately sized they will be used. Misoprostol 
was originally approved by the FDA for reducing the risk of NSAID induced gastric ulcers. It does 
have a black box warning against its use in pregnancy, but then in 2002 had a new label stating 
STUDY00005107
Approval: 9/15/2021

Page 11 of 21 (V.04/20/2016)
its use during pregnancy for cervical ripening and induction of labor. [1] The American Congress 
of Obstetricians and Gynecologists (ACOG) have also supported the use of misoprostol that it is 
a safe and effective form of cervical ripening and induction of labor. [2]
7.4.2
Treatment Regimen
Subject with either receive misoprostol 25 mcg by mouth every 2 hours (range 2-3 hours) or 
misoprostol 25 mcg per vagina every 4 hours (range 4-5 hours). The dosing and protocol for 
each treatment arm is further described in Section 7.1 Study Design. 
7.4.3
Method for Assigning Subject to Treatment Groups
The randomization scheme for this study will use variable-size, random permuted blocks to 
ensure that the number of participants in each treatment arm is balanced after each set of B 
randomized participants, where B is the block size. Furthermore, the randomization will be 
stratified by whether the participant is nulliparous or multiparous. A randomization order will be 
made for oral or vaginal misoprostol through REDCap software. After meeting eligibility criteria 
and being consented for the study, a subject will be ready to be randomized. Team members 
that have REDCap access with access REDCap to carry out the randomization assignment. If they 
do not have access, and a fellow team member is present with access to REDCap, the fellow 
team member will carry out the randomization assignment. If no team member is available with 
REDCap access the Co-PI will be contacted and will enter the relevant subject information into 
REDCap and REDCap will return a randomization assignment. The randomization will then be 
relayed to the study team member to carry out the assigned randomization. If co-PI is not 
available, the PI (Jaimey Pauli) will be contacted to enter the subject’s relevant information into 
REDCap and receive a randomization assignment. If REDCap is offline and unavailable at the 
time of randomization, or the co-PI and Jaimey Pauli were not able to be contacted, 
Investigational Drug Services Pharmacy at Penn State Hershey Medical Center will have 
randomization assignments on paper as a backup hardcopy in order to randomize a patient.
7.4.4
Subject Compliance Monitoring
When the medication is administered, a registered nurse will administer the oral misoprostol 
and a physician will administer the vaginal misoprostol, for which both medications will be 
properly documented as of their time of administration by nursing. 
7.4.5
Blinding of the Test Article
There will be no blinding in this study.
7.4.6
Receiving, Storage, Dispensing and Return 
7.4.6.1 Receipt of Test Article 
The misoprostol tablets will be obtained, prepared, dispensed, returned and 
destroyed by Investigational Drug Services Pharmacy at Penn State Hershey 
Medical Center. Misoprostol 100mcg tablets will be purchased from a pharmacy 
distributor.  The Investigational Pharmacy will divide the 100mcg tablet into four 
pieces under a vertical laminar flow hood and then unit dose the 25mcg ¼ 
tablets.  Each quarter tablet that was produced from the splitting will be 
weighted and the weight will be recorded. Any ¼ tablets judged to be uneven 
will be discarded at the time of preparation. To assist in this judgment, 
pharmacy will weigh 10 tablets of misoprostol to calculate what an average ¼ 
piece should weigh. If a ¼ tablet weighs 5% greater difference than what it’s 
estimated weight should be, it will be discarded. If all 4 pieces appear 
appropriately sized they will be used.
STUDY00005107
Approval: 9/15/2021

Page 12 of 21 (V.04/20/2016)
7.4.6.2 Storage
Prepared misoprostol doses will be stored at controlled room temperature with 
other inpatient investigational medications in Penn State Hershey Medical 
Center Pharmacy.  The Investigational Pharmacy will be responsible for 
maintaining and managing the storage, preparation, dispensation, and 
destruction of the misoprostol for this study following their standard operating 
procedures. 
7.4.6.3 Preparation and Dispensing
The Investigational Pharmacy will divide the 100mcg misoprostol tablet into 
four pieces under a hood and then unit dose the 25mcg ¼ tablets.  Each quarter 
tablet that was produced from the splitting will be weighed and the weight will 
be recorded. Any ¼ tablets judged to be uneven will be discarded at the time of 
preparation.  To assist in this judgment, pharmacy will weigh 10 tablets of 
misoprostol to calculate what an average ¼ piece should weigh. If a ¼ tablet 
weighs 5% greater difference than what it’s estimated weight should be, it will 
be discarded. If all 4 pieces appear appropriately sized they will be used. 
Pharmacy will dispense six ¼ tablets labeled for the specific subject at a time.   
For subjects randomized to receive oral administration of misoprostol, six 
additional ¼ tablets may be dispensed as needed.  The prepared misoprostol ¼ 
tablets (=25mcg) will be the same in both administration arms.  Randomization 
ordering will determine whether the subject receives misoprostol orally 
administered by the registered nurse or vaginally placed by the physician. 
7.4.6.4 Return or Destruction of the Test Article
Misoprostol will be dispensed by pharmacy following receipt of a written study 
order.  Any unused tablets will be returned to pharmacy.  Pharmacy will be 
responsible for proper destruction of the product when applicable. 
7.4.6.5  Prior and Concomitant Therapy
Any medication therapy that is required by the subject for their medical history 
or labor course is permitted during the study. If the subject receives magnesium 
sulfate for seizure prophylaxis due to preeclampsia during their labor course, 
that subject will be accounted for in an intent to treat analysis. 
8.0
Subject Numbers and Statistical Plan
8.1
Number of Subjects
A total of 110 subjects will be randomized.
From looking at previous data collected at Penn State Hershey Medical Center, there were about 350 induction 
of labors using misoprostol over one year’s time. Due to inclusion/exclusion criteria it is estimated that only 60% 
of the induction of labors will qualify for the study. That leaves about 210 patients able to participate in the 
study. Potentially the study could be completed within six months. 
8.2
Sample size determination
With respect to the primary study endpoint of the time interval from administration of misoprostol to active 
phase of labor (greater than or equal to 6 cm dilation), shorter times are considered better. Based on a previous 
published data, the mean time interval from vaginal misoprostol administration to active phase of labor was 
12.0 hours (standard deviation (SD)=5.9 hours) [9] and the mean time interval from oral misoprostol 
administration to active phase of labor was 9.9 hours (SD=7.1 hours). [10] Using these standard deviations and a 
non-inferiority margin of 4 hours, a sample size of 92 patients (46 per group) would provide 80% power to 
STUDY00005107
Approval: 9/15/2021

Page 13 of 21 (V.04/20/2016)
detect non-inferiority of oral misoprostol compared to vaginal misoprostol with respect to the time interval 
from administration of misoprostol to active phase of labor using a one-sided Mann-Whitney test having a 
significance level of 0.025. Factoring in a 15% drop-out rate, our target sample size is 110 subjects. 
8.3
Statistical methods
Analyses will invoke an intent-to-treat paradigm, wherein all randomized subjects are included according to 
their randomized treatment arm, regardless of actual treatment received. Data will be summarized using 
descriptive statistics for continuous variables (mean, standard deviation, number of observations, and 
percentiles) and frequency statistics (frequencies and percentages) for categorical variables. Univariate and 
bivariate distributions will be inspected in order to address any missing data, inconsistent responses, outliers, 
and data entry errors. 
The primary study endpoint will be the time interval from administration of misoprostol to active phase of labor 
(greater than or equal to 6 cm dilation) and shorter time is considered better. The difference between the 
treatment arms (oral misoprostol – vaginal misoprostol) will be denoted by Δ and the non-inferiority margin will 
be set to δ=4 hours. Thus to test for non-inferiority of oral misoprostol compared to vaginal misoprostol the null 
hypothesis is Ho: Δ ≥ 4 hours and the alternative hypothesis is Ha: Δ < 4 hours. The distribution of the time 
interval from administration of misoprostol to active phase of labor (greater than or equal to 6 cm dilation) is 
expected to be skewed. Therefore, to test for non-inferiority of oral misoprostol compared to vaginal 
misoprostol with respect to the primary endpoint, a one-sided Mann-Whitney test will be used where the non-
inferiority margin will be set to 4 hours. The upper bound of the one-sided 97.5% confidence interval for testing 
non-inferiority will be constructed using the Mann-Whitney test as described by Rothman et al. [11] If the upper 
bound of the one-sided 97.5% confidence interval is less than the non-inferiority margin of 4 hours, then the null 
hypothesis will be rejected. In the event the primary endpoint is normally distributed, a one-sided, two-sample 
t-test will be utilized to test for non-inferiority with corresponding one-sided 97.5% confidence interval.
As detailed in Section 1.3, there are numerous secondary endpoints for this study. Secondary continuous 
outcomes (e.g., time interval from administration of misoprostol to initiation of oxytocin for continued 
augmentation of labor and time interval from administration of misoprostol to vaginal delivery) will be 
compared between the two treatment groups using a two-sample t-test or Mann-Whitney test, as appropriate, 
based on the distribution of the outcome. Additionally, as a secondary analysis, Kaplan-Meier survival curves will 
be constructed for these two time to event outcomes. Secondary categorical outcomes (e.g., Section 1.3 
secondary endpoints 3-15 which includes Cesarean section rate and rate of tachysystole) will be compared 
between the two groups using a chi-square test (or Fisher’s exact test if the expected cell counts are small).
While every attempt will be made to collect complete data and prevent participant drop-out, there is the 
possibility of drop-outs and other missed information. We expect the underlying mechanism of any missing data 
for this particular study to arise due to data that are missing-at-random (MAR). One reason the MAR assumption 
is expected for this study is because the two treatment arms are providing the same drug (misoprostol) but via 
different routes (oral vs. vaginal). The statistical methods and analyses that are planned for the primary and 
secondary outcomes are appropriate, and provide valid inference, under the MAR assumption. Although not 
expected for this study, if it appears the MAR assumption is not reasonable then we will use multiple imputation 
to handle the issue of missing data for analyses.
9.0
Confidentiality, Privacy and Data Management 
See the Research Data Plan Review Form 
10.0 Data and Safety Monitoring Plan
STUDY00005107
Approval: 9/15/2021

Page 14 of 21 (V.04/20/2016)
10.1
Periodic evaluation of data
This study involves minimal risk to subjects as it involves standard methods for cervical ripening and 
induction of labor as stated by multiple collaborations including American College of Obstetricians and 
Gynecologists, Cochrane Review, and World Health Organization. Oversight for the conduct of the study 
will be provided by the PI, co-PI, and her mentoring team. They will ensure that all eligibility criteria and 
consent requirements are met prior to a subject’s participation in study and that all study procedures 
and adverse event reporting occur according to the IRB approved protocol. 
10.2
Data that are reviewed
Data collection for safety monitoring: Treatment emergent serious adverse events (TESAEs) are defined 
as uterine rupture, maternal death during her hospitalization, neonatal death (0-28 days of life) related 
to the study drug, and cesarean hysterectomy, and will be reported to the IRB within 24 hours of 
occurrence.  Other adverse events that will be reviewed include postpartum hemorrhage requiring 
blood transfusion, surgical ICU admission, and neonatal NICU admission during mother’s hospital 
admission.
10.3
Method of collection of safety information
All TESAEs (uterine rupture, maternal death during her hospitalization, neonatal death (0-28 days of life) 
related to the study drug, and cesarean hysterectomy) will be documented on study specific case report 
forms. Co-PI, with Jaimey Pauli as second contact, will be notified immediately to begin process of 
notifying the IRB within 24 hours if the event is a TESAE. 
10.4
Frequency of data collection
Data will be collected as the patient is on Labor and Delivery during the time of study. Collected data 
should be entered into the REDCap system within one month’s time of the subject participating in the 
study.  
10.5
Individuals reviewing the data
The PI, Dr. Jaimey Pauli and Co-Investigator will review cumulative adverse events, early termination of 
study participation, and accrual every six months and report any issues requiring modification of the 
study or alteration of the risk:benefit ratio to the IRB immediately. The PI’s will be assisted in reviewing 
the data by Allen Kunselman and Christy Stetter with the Department of Public Health Sciences in the 
Division of Biostatistics and Bioinformatics.
10.6
Frequency of review of cumulative data
The data between the two study groups will be compared on six month intervals.
10.7
Statistical tests
At six month intervals, the percentage of participants experiencing adverse events will be compared 
between the two groups using Fisher’s exact tests; however, stopping of the study will not be based on 
statistical significance. The statistical tests will be used as an aid to help inform the PIs of the safety of 
the study.
10.8
Suspension of research
If the total number of subjects experiencing one or more TESAE (defined as uterine rupture, maternal 
death during her hospitalization, neonatal death (0-28 days of life) related to the study drug, and 
cesarean hysterectomy) reaches 5, the trial will be stopped.  This reflects a 2.3% prevalence rate (110 
subjects with 110 singleton neonates are included in the trial for a prevalence of 5/220 subjects).  Or if 
any two cases of uterine rupture, two cases of maternal death during her hospitalization, or two cases of 
neonatal death (0-28 days of life) related to the study drug, the trial will be stopped. 
STUDY00005107
Approval: 9/15/2021

Page 15 of 21 (V.04/20/2016)
11.0 Risks
Subjects may experience nausea and diarrhea, which is a side effect of misoprostol; subjects may have a higher 
incidence of meconium stained fluid while using misoprostol; uterine tachysystole with or without 
nonreassuring fetal heart tones; development of chorioamnionitis; need for cesarean section; neonatal 
morbidity or death. All of these risks are standard risks of labor and delivery should not be any higher incidence 
due to the study.  There is always a discomfort with sterile vaginal exams. As part of the randomization, if the 
subject is selected to be in the misoprostol administered per vagina, the placement of the medication may cause 
more discomfort than the subjects that take the medication by mouth.
Side Effects/Risks of Misoprostol:

Diarrhea: when taking misoprostol 800 mcg daily, trials have shown an incidence of diarrhea of about 
13%. In this study you will be not receive more than 300 mcg of misoprostol. [1]

Use of vaginal misoprostol has a higher rate of uterine contractions, with contractions being more 
frequent than every 2 minutes when compared with placebo (RR 3.52), dinoprostone gel (RR 1.99), or 
oxytocin (RR 2.24) for induction of labor. [6] Induction with Foley catheter has a decreased risk of uterine 
contractions happening greater than every 2 minutes when compared to vaginal misoprostol (RR 0.15). 
[7] 

Increased risk of meconium staining of amniotic fluid, but no difference in neonatal outcome. [3,6]

Uterine rupture [1]
Side effects of misoprostol when taken as prescribed for prevention of gastric ulcers that have an incidence 
greater than 1%, but no difference than placebo. [1]

Nausea – 3.2%

Flatulence – 2.9%

Headache – 2.4%

Dyspepsia – 2%

Vomiting – 1.3%

Constipation – 1.1%
There is a risk, as with any medication, of an unexpected allergic reaction to the study drug (defined as the 
development of hives, rash, swelling, or difficulty breathing) which will be treated with antihistamines in a 
standard fashion and lead to immediate withdrawal of the subject from the trial.
There is a risk of loss of confidentiality if protected health information or identity is obtained by someone other 
than the investigators, but precautions will be taken to prevent this from happening.  
12.0 Potential Benefits to Subjects and Others
12.1
Potential Benefits to Subjects
Subjects may benefit from a faster labor induction, less need for vaginal exams, easier to administer 
misoprostol for induction of labor, less risk of infection, and decreased rate of cesarean section.
12.2
Potential Benefits to Others
This research may show that misoprostol has a similar or better effect when given orally as compared to 
vaginal administration. Given orally may result in better patient satisfaction, less demand on licensed 
practitioner during induction of labor, less rate of infection, and less cesarean section rate.
13.0 Sharing Results with Subjects
There are no results from diagnostic studies that will be obtained. The study results will be shared with the 
subjects at the end of the project. 
STUDY00005107
Approval: 9/15/2021

Page 16 of 21 (V.04/20/2016)
14.0 Subject Stipend (Compensation) and/or Travel Reimbursements
There is no compensation or reimbursement that will be given to these subjects.
15.0 Economic Burden to Subjects
15.1
Costs 
The misoprostol medication will be provided to the subjects at no cost. There are no extra costs that 
subjects are responsible for because of their participation in this research study. Subjects will assume 
the normal charges from the hospital and staff for Labor and Delivery and Postpartum care. 
15.2
Compensation for research-related injury
It is the policy of the institution to provide neither financial compensation nor free medical treatment for 
research-related injury. In the event of injury resulting from this research, medical treatment is available but will 
be provided at the usual charge. Costs for the treatment of research-related injuries will be charged to subjects 
or their insurance carriers. 
16.0 Resources Available
16.1
Facilities and locations
Identification and notification of subjects will take place at all office locations within the Penn State 
Women’s Health Division, including Hope Drive, Nyes Road, Camp Hill, and Mt. Joy office. Recruitment, 
consent, and study procedures will be performed at Penn State Hershey Medical Center, Labor and 
Delivery Unit. 
16.2
Feasibility of recruiting the required number of subjects
From previous data at Penn State Hershey Medical Center it is estimated that there was about 350 
inductions of labor over one year’s time. Accounting for inclusion/exclusion criteria it is estimated only 
60% of patients will qualify for the study. That leaves 210 patients eligible for the study. Of the 210 
potential subjects, 52% would need to be recruited to complete the study for the projected sample size 
of 110 subjects. 
16.3
PI Time devoted to conducting the research
The Co-Investigator will engage in the study over training remaining at Penn State Hershey Medical 
Center. During her training, there is devoted research time in her residency program for a research 
project such as this one. Assistance from other project members will be provided including Dr. Pauli, PI 
of this project who has dedicated research time.  Dr. Pauli when not in clinic, will have devoted time 
dedicated to research projects. As PI, she will ensure that an allotted time will be well suited to oversee 
the project with the Co-PI.
16.4
Availability of medical or psychological resources
Routine intrapartum and postpartum care. There is no foreseeable extra medical or psychological 
resources needed.
16.5
Process for informing Study Team
All study members will have access to the IRB approved protocol and supporting documents. A copy of 
the study protocol will be available on the Labor and Delivery Unit and in secure location on 
hersheymedfiles.net.  We will have training sessions for all parties involved, study members, physicians 
and nurses, to review the study protocol.  We will have ongoing meetings with research team members 
STUDY00005107
Approval: 9/15/2021

Page 17 of 21 (V.04/20/2016)
for discussions on progress of study and to clarify their duties and expectations to ensure timely 
completion of study.
17.0 Other Approvals
17.1
Other Approvals from External Entities
N/A
17.2
Internal PSU Committee Approvals
Check all that apply:
  Anatomic Pathology – Hershey only – Research involves the collection of tissues or use of pathologic 
specimens. Upload a copy of the Use of Human Tissue For Research Form on the “Supporting 
Documents” page in CATS IRB. This form is available on the IRB website at: 
http://www.pennstatehershey.org/web/irb/home/resources/forms
  Animal Care and Use – All campuses – Human research involves animals and humans or the use of 
human tissues in animals
  Biosafety – All campuses – Research involves biohazardous materials (human biological specimens 
in a PSU research lab, biological toxins, carcinogens, infectious agents, recombinant viruses or DNA or 
gene therapy). 
  Clinical Research Center (CRC) Advisory Committee – Research involves the use of CRC services in 
any way.  
  Conflict of Interest Review – All campuses – Research has one or more of study team members 
indicated as having a financial interest.
  Radiation Safety – Hershey only – Research involves research-related radiation procedures. All 
research involving radiation procedures (standard of care and/or research-related) must upload the 
Radiation Review Form on the “Supporting Documents” page in CATS IRB. This form is available on the 
IRB website at: http://www.pennstatehershey.org/web/irb/home/resources/forms
  IND/IDE Audit – All campuses – Research in which the PSU researcher holds the IND or IDE or 
intends to hold the IND or IDE.
  Scientific Review – Hershey only – All investigator-written research studies requiring review by the 
convened IRB must provide documentation of scientific review with the IRB submission. The scientific 
review requirement may be fulfilled by one of the following: (1) external peer-review process; (2) 
department/institute scientific review committee; or (3) scientific review by the Clinical Research Center 
Advisory committee.  NOTE: Review by the Penn State Hershey Cancer Institute Scientific Review 
Committee is required if the study involves cancer prevention studies or cancer patients, records and/or 
tissues. For more information about this requirement see the IRB website at: 
http://www.pennstatehershey.org/web/irb/home/resources/investigator 
18.0 Multi-Site Research
N/A
STUDY00005107
Approval: 9/15/2021

Page 18 of 21 (V.04/20/2016)
19.0 Adverse Event Reporting
19.1
Adverse Event Definitions
For drug studies, incorporate the following definitions into the below responses, as written:
Adverse event
Any untoward medical occurrence associated with the use of the drug in 
humans, whether or not considered drug related
Adverse reaction
Any adverse event caused by a drug
Suspected adverse 
reaction
Any adverse event for which there is a reasonable possibility that the drug 
caused the adverse event.  Suspected adverse reaction implies a lesser degree 
of certainty about causality than “adverse reaction”.

Reasonable possibility.  For the purpose of IND safety reporting, 
“reasonable possibility” means there is evidence to suggest a causal 
relationship between the drug and the adverse event.
Serious adverse 
event or Serious 
suspected adverse 
reaction
Serious adverse event or Serious suspected adverse reaction: An adverse event 
or suspected adverse reaction that in the view of either the investigator or 
sponsor, it results in any of the following outcomes: Death, a life-threatening 
adverse event, inpatient hospitalization or prolongation of existing 
hospitalization, a persistent or significant incapacity or substantial disruption 
of the ability to conduct normal life functions, or a congenital anomaly/birth 
defect. Important medical events that may not result in death, be life-
threatening, or require hospitalization may be considered serious when, based 
upon appropriate medical judgment, they may jeopardize the patient or 
subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. 
Life-threatening 
adverse event or 
life-threatening 
suspected adverse 
reaction
An adverse event or suspected adverse reaction is considered “life-
threatening” if, in the view of either the Investigator (i.e., the study site 
principal investigator) or Sponsor, its occurrence places the patient or research 
subject at immediate risk of death.  It does not include an adverse event or 
suspected adverse reaction that had it occurred in a more severe form, might 
have caused death.
Unexpected 
adverse event or 
Unexpected 
suspected adverse 
reaction.  
An adverse event or suspected adverse reaction is considered “unexpected” if 
it is not listed in the investigator brochure, general investigational plan, clinical 
protocol, or elsewhere in the current IND application; or is not listed at the 
specificity or severity that has been previously observed and/or specified.
19.2
Recording of Adverse Events
In accordance with applicable policies of The Pennsylvania State University Institutional Review Board 
(IRB), the investigator will report, to the IRB, any observed or reported harm (adverse event) 
experienced by a subject or other individual, which in the opinion of the investigator is determined to be 
(1) unexpected; and (2) probably related to the research procedures. Harms (adverse events) will be 
submitted to the IRB in accordance with the IRB policies and procedures.
19.3
Causality and Severity Assessments
The investigator will promptly review documented adverse events and abnormal test findings to 
determine 1) if the abnormal test finding should be classified as an adverse event; 2) if there is a 
reasonable possibility that the adverse event was caused by the study drug(s) or device(s); and 3) if the 
adverse event meets the criteria for a serious adverse event.
STUDY00005107
Approval: 9/15/2021

Page 19 of 21 (V.04/20/2016)
If the investigator’s final determination of causality is “unknown and of questionable relationship to the 
study drug(s) or device(s)”, the adverse event will be classified as associated with the use of the study 
drug(s) or device(s) for reporting purposes.  If the investigator’s final determination of causality is 
“unknown but not related to the study drug(s) or device(s)”, this determination and the rationale for the 
determination will be documented in the respective subject’s case history.
19.4
Reporting Adverse Reactions and Unanticipated Problems to the Responsible IRB
In accordance with applicable policies of The Pennsylvania State University Institutional Review Board 
(IRB), the investigator will report, to the IRB, any observed or reported harm (adverse event) 
experienced by a subject or other individual, which in the opinion of the investigator is determined to be 
(1) unexpected; and (2) probably related to the research procedures. Harms (adverse events) will be 
submitted to the IRB in accordance with the IRB policies and procedures.
19.5
Unblinding Procedures
The study is not blinded, therefore N/A
19.6
Stopping Rules
If the total number of subjects experiencing one or more serious adverse events (defined as uterine 
rupture, maternal death during her hospitalization, neonatal death during maternal hospitalization, and 
cesarean hysterectomy) reaches 5, the trial will be stopped.  This reflects a 2.3% prevalence rate (110 
subjects with 110 singleton neonates are included in the trial for a prevalence of 5/220 subjects).  Or if 
any two cases of uterine rupture, two cases of maternal death during her hospitalization, or two cases of 
neonatal death (0-28 days of life) related to the study drug, the trial will be stopped.
20.0 Study Monitoring, Auditing and Inspecting
20.1
Study Monitoring Plan
20.1.1 Quality Assurance and Quality Control
The study will be monitored by Clinical Trial Monitoring Team from the Department of Public 
Health Sciences at Penn State Hershey College of Medicine. The monitors will provide an 
independent review of the regulatory and subject records and data collected to assure 
compliance with the protocol, GCP, and applicable federal regulations. The monitoring will occur 
at regular intervals after the enrollment of the first subject, after enrollment of the fifth subject 
and then after every 10 subjects enrolled or at a frequency developed by the Public Health 
Sciences monitoring team. 
20.1.2 Safety Monitoring
On the listed protocol that investigators will follow while carrying out the study, will be the list 
of treatment emergent serious adverse events (TESAEs). Treatment emergent serious adverse 
events are defined as maternal death during hospital admission, neonatal death (0-28 days of 
life) related to the study drug, uterine rupture, or cesarean hysterectomy. If a TESAE happens 
the Co-investigator will be immediately paged and notified. If no response within 4 hours, the 
Principal Investigator, Jaimey Pauli, will be paged. 
The Principal Investigator will confirm that the TESAE are correctly entered into the adverse 
event (AE) case report forms by the Co-investigator; be available to answer any questions that 
the Co-investigator may have concerning AEs; and will notify the IRB and FDA all TESAEs. All 
assessments of AEs will be made by a licensed medical professional who is an investigator on 
the research. 
STUDY00005107
Approval: 9/15/2021

Page 20 of 21 (V.04/20/2016)
The Co-investigator will complete the appropriate report form and logs; assist the PI to prepare 
reports and notify the IRB and FDA of all Unanticipated Problems/TESAE’s.
The Clinical Trial Monitoring Team will confirm that the TESAEs and AEs are correctly entered 
into the case report forms. The monitoring team will also confirm that the adverse events are 
consistent with the source documents and are reported to the appropriate regulatory bodies as 
required. 
21.0 Future Undetermined Research: Data and Specimen Banking
21.1
Data and/or specimens being stored
N/A
21.2
Location of storage
N/A
21.3
Duration of storage
N/A
21.4
Access to data and/or specimens
N/A
21.5
Procedures to release data or specimens
N/A
21.6
Process for returning results
N/A
22.0 References
1.
Pfizer, Inc. (2012). Prescribing Information: Cytotec [package insert]. New York, NY: G.D. Serarle, Division of 
Pfizer Inc. Reference ID: 3217917.
2.
Ramirez, M. and Ramin, S. (2009). ACOG Practice Bulletin No. 107: Induction of Labor. Obstetrics & 
Gynecology, 386-397.
3.
Alfirevic, Z. Aflaifel, N., & Weeks, A. (2014). Oral misoprostol for induction of labour. Cochrane Database of 
Systematic Reviews, (6). Doi:10.1002/14651858.CD001338.pub3.
4.
Tang, J., Kapp, N., Drogoman, M. & Souza, J.P. (2013). WHO recommendations for misoprostol use for 
obstetric and gynecologic indications. International Journal of Gynecology & Obstetrics, 121(2), 186-189.
5.
Zieman, M., Fong, S., Benowitz, N., Banskter, D., &Darney, P. (1997). Absorption kinetics of misoprostol with 
oral or vaginal administration. Obstetrics & Gynecology, 90(1), 88-92.
6.
Hofmeyr, G. J., Gulmezoglu, A. M., & Pileggi, C. (2010). Vaginal misoprostol for cervical ripening and 
induction of labour. Cochrane Database of Systematic Reviews.
7.
Chen, W., Xue, J.,Peprah, M., Wen, S., Walker, M. Gao, Y., & Tang, Y. (2015). A systematic review and 
network meta-analysis comparing the use of Foley catheters, misoprostol, and dinoprostone for cervical 
ripening in the induction of labour. BJOG: An International Journal of Obstetrics & Gynaecology BJOG: Int J 
Obstet Gy, 123(3), 346-354.
8.
Alfirevic, Z., Keeney, E., Dowswell, T., Welton, N. J., Dias, S., Jones, L. V., Navaratnam, K., & Caldwell, D. M. 
(2015). Labour induction with prostaglandins: A systematic review and network meta-analysis. Bmj, 
350(Feb05 10). 
9.
Perry, K. G., Larmon, J., May, W. L., Robinette, L. G., & Martin, R. W. (1998). Cervical ripening: A randomized 
comparison between intravaginal misoprostol and an intracervical balloon catheter combined with 
intravaginal dinoprostone. American Journal of Obstetrics and Gynecology, 178(6), 1333-1340. 
10. Thaisomboon, A., Russameecharoen, K., Wanitpongpan, P., Phattanachindakun, B., & Changnoi, A. (2012). 
Comparison of the efficacy and safety of titrated oral misoprostol and a conventional oral regimen for 
cervical ripening and labor induction. International Journal of Gynecology & Obstetrics, 116(1), 13-16. 
11. Rothman MD, Wiens BL, Chan ISF. (2012) Design and Analysis of Non-Inferiority Trials. Boca Raton, FL: 
Chapman & Hall/CRC, pp. 350-353.
STUDY00005107
Approval: 9/15/2021

Page 21 of 21 (V.04/20/2016)
STUDY00005107
Approval: 9/15/2021

Version Date:  2/1/2021
Page 1 of 8 (v.02/22/2016)
CONSENT FOR RESEARCH
Penn State College of Medicine
The Milton S. Hershey Medical Center
Title of Project:  
A comparison of oral misoprostol versus vaginal misoprostol for cervical ripening and 
induction of labor.
Principal Investigator:
      Jaimey M. Pauli, MD
Co-Principal Investigator:     Courtney Birchall, MD
Address:     500 University Drive, M/C H103
                    Hershey, PA 17033
Telephone Numbers: Weekdays: 8:00 a.m. to 5:00 p.m. (717) 531-3503 or (717) 531-8521 and pager 3192
After hours call (717) 531-8521.  Ask for the OB/GYN doctor on 24-hour call.
Subject’s Printed Name: _____________________________
We are asking you to be in a research study.
Whether or not you take part is up to you. You can choose not to take part. You can agree to take part 
and later change your mind. Your decision will not be held against you.
This form gives you information about the research. Please ask questions about anything that is 
unclear to you and take your time to make your choice.
1.   Why is this research study being done?   
We are asking you to be in this research because you are scheduled for a term induction of labor at 
Penn State Hershey Medical Center.
This drug, misoprostol, has been approved by the Food and Drug Administration for the treatment 
of reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin) induced 
gastric ulcers in patients at high risk of complications from gastric ulcers and is commercially 
available. Misoprostol is routinely used and approved by The American College of Obstetricians and 
Gynecologists as a cervical ripening agent for the induction of labor. A cervical ripening agent is a 
process to aid one’s body in preparing for labor. The purpose of this study is to compare the effects 
of misoprostol on cervical ripening and induction of labor when it is administered either via the 
standard method, vaginally, or the experimental method, by mouth. 
Approximately 110 people will take part in this research study Hershey Medical Center. 
2.   What will happen in this research study?
In the office at one of your prenatal visits, your physician or advanced practitioner may have reviewed 
the study with you. If he/she felt you are eligible to continue in the study, when he/she schedules your 
induction of labor, a form is routinely sent to our schedulers. A notation will be made on the form stating 
potential misoprostol study candidate for which it will be a reminder to the physicians on Labor and 
Delivery to discuss with you participating in the study if you qualify. 
STUDY00005107
Approval: 9/15/2021
Approval End Date: 9/14/2022

Version Date:  2/1/2021
Page 2 of 8 (v.02/22/2016)
Upon arrival to Labor and Delivery at Hershey Medical Center you will undergo standard check-in process 
with nursing and physician. You will have routine electronic fetal monitoring (EFM), monitoring for 
contractions, hemoglobin level, blood type, a peripheral intravenous line started, sterile vaginal exam, 
and review and sign Cesarean Section Consent. All of these screening tests would be done even if you 
do not take part in this research study. These tests are routine for patients when you arrive for 
induction of labor who are about to start therapy. If you meet the inclusion criteria for the study you 
will be randomly assigned to receive one of the two study treatments. This means that whichever 
study treatment you receive will be determined purely by chance, like flipping a coin. Either you will 
be in the research arm and given misoprostol 25 micrograms (mcg) orally every two hours or in the 
standard arm and given misoprostol 25 mcg vaginally every four hours. 
Once consented for, randomized, and participating in the study, the research team will be following the 
below guidelines: 

During misoprostol administration there will be a sterile vaginal exam every 4 hours which is 
standard of care. 

Once you reach a sterile vaginal exam with a Bishop score of greater than or equal to 8 or your 
cervix dilates to greater than or equal to 4 cm, misoprostol will be discontinued and oxytocin will 
be initiated 2 or 4 hours after the last dose of misoprostol if indicated for further augmentation 
of labor. 

If receiving misoprostol per vagina, you may only have a max of 6 doses of misoprostol for at 
total of 150 mcg. If receiving misoprostol per mouth, you may only have a max of 12 doses of 
misoprostol for a total of 300 mcg. 

After misoprostol is discontinued and/or oxytocin is initiated, you will have a sterile vaginal exam 
every 2 hours which is the standard of care.

If you do not undergo spontaneous rupture of membranes, the physician may augment your 
labor with artificial rupture of membranes after the initiation of oxytocin. 

Your labor induction, augmentation, and delivery will be monitored and treated with Hershey 
Medical Center’s standard protocol. 
What are my responsibilities if I take part in this research? 
If you take part in this research, your major responsibilities will include: 

Follow the instructions of the research team as outlined above. 
3.   What are the risks and possible discomforts from being in this research study?  
You will be assigned to a treatment program by chance. The treatment you receive may prove to be 
less effective or to have more side effects than the other research treatment(s) or other available 
treatments.
There is always a discomfort with sterile vaginal exams. As part of the randomization, if you selected to 
be in the misoprostol administered per vagina, the placement of the medication may cause more 
discomfort than if you had to take the medication by mouth. The risk for possible cesarean section 
throughout the course of your induction of labor, chorioamnionitis, neonatal morbidity or death is 
standard and you would have these risks with or without this research study. 
Side Effects/Risks of Misoprostol:

Diarrhea: when taking misoprostol 800 mcg daily, trials have shown an incidence of diarrhea of about 
13%. In this study you will be not receive more than 300 mcg of misoprostol. 
STUDY00005107
Approval: 9/15/2021
Approval End Date: 9/14/2022

Version Date:  2/1/2021
Page 3 of 8 (v.02/22/2016)

Use of vaginal misoprostol has a higher rate of uterine contractions, with contractions being more 
frequent than every 2 minutes when compared with placebo, dinoprostone gel, or oxytocin for 
induction of labor. Induction with Foley catheter has a decreased risk of uterine contractions 
happening greater than every 2 minutes when compared to vaginal misoprostol. 

Increased risk of meconium staining of amniotic fluid, but no difference in neonatal outcome. 
Meconium staining means that your infant had a bowel movement inside the womb prior to birth. It 
happens in about 12-22 percent of the time. 

Uterine rupture
Side effects of misoprostol when taken as prescribed for prevention of gastric ulcers that have an 
incidence greater than 1%, but no difference than placebo. 

Nausea – 3.2%

Flatulence – 2.9%

Headache – 2.4%

Dyspepsia – 2% (indigestion or heartburn)

Vomiting – 1.3%

Constipation – 1.1%
There is a risk, as with any medication, of an unexpected allergic reaction to the study drug (defined 
as the development of hives, rash, swelling, or difficulty breathing) which will be treated with 
antihistamines in a standard fashion and lead to removal from the trial to prevent any further 
allergic reaction to the medication.
There is a risk of loss of confidentiality if your information or your identity is obtained by someone other 
than the investigators, but precautions will be taken to prevent this from happening. The confidentiality 
of your electronic data created by you or by the researchers will be maintained to the degree permitted 
by the technology used. 
4.   What are the possible benefits from being in this research study?   
4a.  What are the possible benefits to me?
There is no guarantee that you will benefit from this research. The possible benefits you may 
experience from this research study include A faster labor induction, less need for vaginal exams, easier 
to administer misoprostol for induction of labor, less risk of infection, and decreased rate of cesarean 
section.
    
4b. What are the possible benefits to others?
The results of this research may gain further understanding of using oral misoprostol for 
induction of labor with the new recommended dosing to provide better patient satisfaction, 
fewer  vaginal exams, less rates of infection, decreased rate of cesarean section and decreased 
uterine tachysystole. 
5.   What other options are available instead of being in this research study?
You do not have to take part in this study to be treated for your condition. Instead of participating in 
this research, you could:

Receive the routine standard induction of labor as discussed with your provider. Options are 
vaginal misoprostol at the same dosing without participating in the study, use of a Foley 
catheter causing mechanical dilation, or oxytocin. 
STUDY00005107
Approval: 9/15/2021
Approval End Date: 9/14/2022

Version Date:  2/1/2021
Page 4 of 8 (v.02/22/2016)
Before you decide if you want to be in this research, we will discuss the other choices that are available 
to you.  We will tell you about the possible benefits and risks of these choices.
The therapy (vaginal dosing) offered in this research is available to you without taking part in this 
research study. The oral misoprostol dosing is not available to you at this site outside of this research 
study. 
6.   How long will I take part in this research study?
If you agree to take part, it will take you approximately 12-36 hours and up to 72+ hours to 
complete this research study, which is the normal time frame for an induction of labor. Once your 
infant is delivered there is no further time commitment to this study. 
7.   How will you protect my privacy and confidentiality if I decide to take part in this research study?
7a.  What happens to the information collected for the research?
Efforts will be made to limit the use and sharing of your personal research information. In our research 
files at The Milton S. Hershey Medical Center (HMC) and Penn State College of Medicine (PSU) we will 
include these identifiers;  your name, date of birth, medical record number, and a code number. 

A list that matches your name with your code number will be kept in a locked file in the Penn State 
Milton S. Hershey Medical Center, Maternal Fetal Medicine Office.

Your research records will be labeled with your code number, name, date of birth, and medical 
record number and will be kept in a safe and locked area in the Maternal Fetal Medicine Office.

A copy of this signed consent form will be included in your HMC medical record. This means that 
other HMC healthcare providers will know you are in this study. 
In the event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared.
7b. How will my identifiable health information be used?
If you give your consent, health information that can be traced to you will be collected for this research 
study. In general, under federal law, health information is private. However, there are exceptions to this 
rule, and you should know who may be able to see, use, and share your health information for research 
and why they may need to do so. We will use and disclose your information only as described in this 
form and in the HMC Privacy Notice.
The research team may use the following health information:

Past, present, and future medical records

New health information from tests, procedures, visits, interviews, or forms filled out as part of 
this research study.
The following people/groups may see, use, and share your identifiable health information:

HMC/PSU research staff involved in this study

The HMC/PSU Institutional Review Board (IRB), a group of people who review the research 
study to protect subjects’ rights and welfare

The HMC/PSU Human Subjects Protection Office

The HMC/PSU Research Quality Assurance Office

Non-research staff within HMC/PSU who need this information to do their jobs (such as for 
treatment, payment (billing), or health care operations)
STUDY00005107
Approval: 9/15/2021
Approval End Date: 9/14/2022

Version Date:  2/1/2021
Page 5 of 8 (v.02/22/2016)

Federal and state agencies (such as the U.S. Food and Drug Administration, the Office for 
Human Research Protections, the Department of Health and Human Services, the National 
Institutes of Health, and other U.S. or foreign government bodies that oversee or review 
research)

The HMC/PSU pharmacy

A group that oversees the data (study information) and safety of this research

Organizations that provide independent accreditation and oversight of hospitals and research
These groups may also review and/or copy your original PSU/HMC records while looking at the results 
of the research study.  It is possible that some of the other people/groups who receive your health 
information may not be required by Federal privacy laws to protect your information. We share your 
information only when we must, and we ask anyone who receives it from us to protect your privacy. 
Because research is an ongoing process, your permission for the use, storage and sharing of your health 
information will continue indefinitely. 
Your privacy rights:

You have the right to refuse to sign this form that allows us to use and share your health 
information for research; however, if you don’t sign it, you will not be able to take part in this 
research study.

You have the right to withdraw your permission for us to use or share your health information 
for this research study. If you want to withdraw your permission, you must notify the person in 
charge of this research study in writing using the address on the front of this form. Once 
permission is withdrawn, you cannot continue to take part in the study. 

If you withdraw your permission, we will stop collecting health information about you for this 
study; we may continue to use and share your health information that we already have if it is 
necessary for safety and scientific soundness of the research study; and we will not be able to 
take back information that has already been used or shared with others. 

You have the right to see and get a copy of your health information that is used or shared for 
treatment or for payment. However, you may not be allowed to see or copy certain health 
information that is a part of this research study. This is only for the period of the study. You will 
be allowed to see that information when the entire research study is complete. 
           
8.   What are the costs of taking part in this research study?
8a. What will I have to pay for if I take part in this research study? 
For costs of tests and procedures that are only being done for the research study: 

The misoprostol drug will be provided by the Investigational Drug Services Pharmacy at Penn 
State Hershey Medical Center at no cost to you while you take part in this study. Although the 
study drugs are provided at no cost, there may be costs for drug administration. You or your 
insurance company will be responsible for these costs. 

There are no extra tests or procedures that are required as part of the research that are outside 
the standard of care (what is normally done) for an induction of labor. 
For costs of medical services for care you would receive even if you were not in this research study:

You and/or your insurance company will be responsible for the cost of routine medications, 
tests and procedures that you would receive even if you were not in this research.

You and/or your insurance company will be billed for the costs of these routine tests and 
procedures in the usual manner.
STUDY00005107
Approval: 9/15/2021
Approval End Date: 9/14/2022

Version Date:  2/1/2021
Page 6 of 8 (v.02/22/2016)

You will be responsible for any co-payments, co-insurance and deductibles that are standard 
for your insurance coverage. 

You will be responsible for any charges not reimbursed by your insurance company.

Some insurance companies may not pay for routine costs for people taking part in research 
studies. Before deciding to be in this research you should check with your insurance company 
to find out what they will pay for. 
If you have any questions about costs and insurance, ask the research study doctor or a member of the 
research team. 
8b. What happens if I am injured as a result of taking part in this research study?
It is possible that you could develop complications or injuries as a result of being in this research study. 
If you experience a side effect or injury and emergency medical treatment is required, seek 
treatment immediately at any medical facility. If you experience a side effect or injury and you 
believe that emergency treatment is not necessary, you should contact the principal investigator 
listed on the first page of this consent form as soon as possible and the principal investigator will 
arrange for medical treatment.
HMC/PSU compensation for injury

There are no plans for HMC/PSU to provide financial compensation or free medical treatment 
for research-related injury. 

If an injury occurs, medical treatment is available at the usual charge. 

Costs will be charged to your insurance carrier or to you. 

Some insurance companies may not cover costs associated with research injuries. 

If these costs are not covered by your insurance, they will be your responsibility.
When you sign this form you are not giving up any legal right to seek compensation for injury. 
9.
Will I be paid to take part in this research study?
You will not receive any payment or compensation for being in this research study.
10. Who is paying for this research study?
The institution and investigators are not receiving any funds to support this research study.         
11.  What are my rights if I take part in this research study?
Taking part in this research study is voluntary. 

You do not have to be in this research. 

If you choose to be in this research, you have the right to stop at any time. 

If you decide not to be in this research or if you decide to stop at a later date, there will be no 
penalty or loss of benefits to which you are entitled. 
If you decide to leave the research, contact the investigator or study team so that the study team and 
physicians can continue your induction of labor as you both seem fit to the standard of care. 
If you stop being in the research, already collected data may not be removed from the study database. 
You will be asked whether the investigator can collect medical information from your routine medical 
care. If you agree, this data will be handled the same as research data. If you withdraw completely from 
the research study, no further information will be collected and your participation will end. You may 
STUDY00005107
Approval: 9/15/2021
Approval End Date: 9/14/2022

Version Date:  2/1/2021
Page 7 of 8 (v.02/22/2016)
discontinue taking part at any time without penalty or loss of benefits to which you are otherwise 
entitled.
Your research doctor may take you out of the research study without your permission. 

Some possible reasons for this are: allergic reaction to misoprostol, uterine tachysystole (too 
many contractions within a 10 minute period), or nonreasurring fetal heart tones. 

Also, the sponsor of the research may end the research study early. 

If your participation ends early, you will receive routine care during labor, delivery, and 
postpartum period at Penn State Hershey Medical Center. 
During the course of the research you will be provided with any new information that may affect your 
health, welfare or your decision to continue participating in this research.
12. If I have questions or concerns about this research study, whom should I call?    
Please call the Co-Principal Investigator of the research study, Dr. Courtney Birchall at 717-531-3503 or 
the OB/GYN doctor on 24-hour call at 717-531-8521 if you:

Have questions, complaints or concerns about the research.

Believe you may have been harmed by being in the research study.  
You may also contact the research protection advocate in the HMC Human Subjects Protection Office 
(HSPO) at 717-531-5687 if you:

Have questions regarding your rights as a person in a research study.

Have concerns or general questions about the research. 

Have questions about your privacy and the use of your personal health information. 

You may also call this number if you cannot reach the research team or wish to offer input or 
to talk to someone else about any concerns related to the research. 
You may visit the HSPO’s web site at http://pennstatehershey.org/irb under research subject 
information for:

Information about your rights when you are in a research study; 

Information about the Institutional Review Board (IRB), a group of people who review the 
research to protect your rights; and 

Links to the federal regulations and information about the protection of people who are in 
research studies. If you do not have access to the internet, copies of these federal regulations 
are available by calling the HSPO at (717) 531-5687.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. 
Law. This Web site will not include information that can identify you. At most, the Web site will include 
a summary of the results. You can search this Web site at any time.
INFORMED CONSENT AND AUTHORIZATION TO TAKE PART IN RESEARCH 
Signature of Person Obtaining Informed Consent
Your signature below means that you have explained the research to the subject or subject 
representative and have answered any questions he/she has about the research.
______________________________
__________
______      
________________
Signature of person who explained this research Date
Time
              Printed Name
STUDY00005107
Approval: 9/15/2021
Approval End Date: 9/14/2022

Version Date:  2/1/2021
Page 8 of 8 (v.02/22/2016)
(Only approved investigators for this research may explain the research and obtain informed consent.)  
Signature of Person Giving Informed Consent and Authorization
Before making the decision about being in this research you should have:

Discussed this research study with an investigator, 

Read the information in this form, and

Had the opportunity to ask any questions you may have. 
Your signature below means that you have received this information, have asked the questions you currently 
have about the research and those questions have been answered. You will receive a copy of the signed and 
dated form to keep for future reference.
Signature of Subject
By signing this consent form, you indicate that you voluntarily choose to be in this research and agree to 
allow your information to be used and shared as described above. 
___________________________
__________
______      
________________ 
Signature of Subject 
Date
Time
Printed Name
STUDY00005107
Approval: 9/15/2021
Approval End Date: 9/14/2022